Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Sio Gene Therapies Inc.SIOX · Entity 130622 | Chief R&D Officer | April 15, 2021 | April 19, 2021 |
| Verrica Pharmaceuticals Inc.VRCA · Entity 6823 | Director | June 05, 2026 | June 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Sio Gene Therapies Inc.
Report date April 15, 2021 · Filed April 19, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.47 · Expires 2031-04-14 | Direct | 244,300 |
Reported balance
After 2021-04-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-04-15 · Grant · Acquired 244,300 · Balance 244,300 F1: The option vests over a period of three years with one-third of the shares of common stock underlying the option vesting on April 15, 2022 and the remainder vesting in 8 equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer on each such date. The option allows for early exercise, subject to the Issuer's repurchase option with respect to any unvested shares of common stock. All shares of common stock underlying the option will become fully vested upon a change in control, as that term is defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests over a period of three years with one-third of the shares of common stock underlying the option vesting on April 15, 2022 and the remainder vesting in 8 equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer on each such date. The option allows for early exercise, subject to the Issuer's repurchase option with respect to any unvested shares of common stock. All shares of common stock underlying the option will become fully vested upon a change in control, as that term is defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan.
Verrica Pharmaceuticals Inc.
Report date June 05, 2026 · Filed June 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.04 · Expires 2036-06-04 | Direct | 16,000 |
Reported balance
After 2026-06-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 16,000 · Balance 16,000 F1: The shares underlying this option shall vest and become exercisable in 12 equal monthly installments beginning on July 5, 2026 and, in any event, will be fully vested on the date of the next annual meeting of stockholders, subject to continued service as a director through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option shall vest and become exercisable in 12 equal monthly installments beginning on July 5, 2026 and, in any event, will be fully vested on the date of the next annual meeting of stockholders, subject to continued service as a director through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 05, 2026 Filed Jun 9, 2026 20:15 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantStock Option (right to buy) · Derivative | 16,000 | $0.00 Strike: $6.04 | $0.00 |
DisclosureSEC source: 0001745995-26-000002 · form4-06092026_040608.xml · derivative · entry 1 Corcoran Gavin · CIK 0001745995 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2036-06-04 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in 12 equal monthly installments beginning on July 5, 2026 and, in any event, will be fully vested on the date of the next annual meeting of stockholders, subject to continued service as a director through the applicable vesting date. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 20:45 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $0.58 | $0.00 |
DisclosureSEC source: 0001415889-25-016290 · form4-06092025_040607.xml · derivative · entry 1 Corcoran Gavin · CIK 0001745995 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2035-06-04 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in 12 equal monthly installments beginning on July 5, 2025 and, in any event, will be fully vested on the date of the next annual meeting of stockholders, subject to continued service as a director through the applicable vesting date. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 20:32 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantStock Option (right to buy) · Derivative | 17,502 | $0.00 Strike: $0.44 | $0.00 |
DisclosureSEC source: 0001415889-25-009654 · form4-04022025_080448.xml · derivative · entry 1 Corcoran Gavin · CIK 0001745995 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,502 Underlying: Common Stock · 17,502 shares Expires 2035-03-31 F1 · derivative.exercise_date: 1/3rd of the total shares subject to the option shall vest on March 31, 2026, and 1/36th of the total shares subject to the option shall vest in 24 monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| April 15, 2021 Filed Apr 19, 2021 16:52 UTC | Sio Gene Therapies Inc. SIOX · Entity 130622 | GrantStock Option (Right to Buy) · Derivative | 244,300 | $0.00 Strike: $2.47 | $0.00 |
DisclosureSEC source: 0001636050-21-000045 · wf-form4_161886555787737.xml · derivative · entry 1 Corcoran Gavin · CIK 0001745995 · Chief R&D Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,300 Underlying: Common Stock · 244,300 shares Expires 2031-04-14 F1 · derivative.exercise_date: The option vests over a period of three years with one-third of the shares of common stock underlying the option vesting on April 15, 2022 and the remainder vesting in 8 equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer on each such date. The option allows for early exercise, subject to the Issuer's repurchase option with respect to any unvested shares of common stock. All shares of common stock underlying the option will become fully vested upon a change in control, as that term is defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan. Read SEC document |
| March 17, 2021 Filed Mar 19, 2021 16:58 UTC | Sio Gene Therapies Inc. SIOX · Entity 130622 | Disposition to issuerRestricted Stock Units · Derivative | 16,001 | $0.00 | $0.00 |
DisclosureSEC source: 0001636050-21-000029 · wf-form4_161618749134988.xml · derivative · entry 2 Corcoran Gavin · CIK 0001745995 · Chief R&D Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,001 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of the Issuer's common stock. The shares of common stock underlying the restricted stock units vested on July 31, 2020 but settlement of the restricted stock units was delayed until transactions acceptable under the Issuer's insider trading policy were permitted. F1 · derivative.exercise_date: Each restricted stock unit represents the right to receive one share of the Issuer's common stock. The shares of common stock underlying the restricted stock units vested on July 31, 2020 but settlement of the restricted stock units was delayed until transactions acceptable under the Issuer's insider trading policy were permitted. F1 · derivative.expiration_date: Each restricted stock unit represents the right to receive one share of the Issuer's common stock. The shares of common stock underlying the restricted stock units vested on July 31, 2020 but settlement of the restricted stock units was delayed until transactions acceptable under the Issuer's insider trading policy were permitted. Read SEC document |
| March 17, 2021 Filed Mar 19, 2021 16:58 UTC | Sio Gene Therapies Inc. SIOX · Entity 130622 | GrantCommon Stock | 16,001 | $0.00 | $0.00 |
DisclosureSEC source: 0001636050-21-000029 · wf-form4_161618749134988.xml · nonDerivative · entry 1 Corcoran Gavin · CIK 0001745995 · Chief R&D Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,792 Read SEC document |
| June 12, 2020 Filed Jun 15, 2020 19:38 UTC | Sio Gene Therapies Inc. AXGT · Entity 130622 | Disposition to issuerRestricted Stock Units · Derivative | 16,002 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-036804 · doc4.xml · derivative · entry 3 Corcoran Gavin · CIK 0001745995 · Chief R&D Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,001 Underlying: Common Shares · 16,002 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of the Issuer's common stock. 50% of the common shares underlying the restricted stock units vested on January 31, 2020 but settlement of such portion of the restricted stock units was delayed until transactions acceptable under the Issuer's insider trading policy were permitted F3 · derivative.exercise_date: 50% of the common shares underlying the restricted stock units vest on January 31, 2020 and the remainder vest on July 31, 2020, subject to the Reporting Person providing continuous service to the Issuer through each such date. F3 · derivative.expiration_date: 50% of the common shares underlying the restricted stock units vest on January 31, 2020 and the remainder vest on July 31, 2020, subject to the Reporting Person providing continuous service to the Issuer through each such date. Read SEC document |
| June 12, 2020 Filed Jun 15, 2020 19:38 UTC | Sio Gene Therapies Inc. AXGT · Entity 130622 | Tax withholdingCommon Shares | 6,211 | $3.46 | $21,490.06 |
DisclosureSEC source: 0001209191-20-036804 · doc4.xml · nonDerivative · entry 2 Corcoran Gavin · CIK 0001745995 · Chief R&D Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,791 F1 · shares: The shares were sold on behalf of the Reporting Person in the open market to cover withholding taxes relating to the settlement of the vested restricted stock units. Read SEC document |
| June 12, 2020 Filed Jun 15, 2020 19:38 UTC | Sio Gene Therapies Inc. AXGT · Entity 130622 | GrantCommon Shares | 16,002 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-036804 · doc4.xml · nonDerivative · entry 1 Corcoran Gavin · CIK 0001745995 · Chief R&D Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,002 Read SEC document |
| April 15, 2020 Filed Apr 17, 2020 21:04 UTC | Sio Gene Therapies Inc. AXGT · Entity 130622 | GrantRestricted Stock Units · Derivative | 42,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-025017 · doc4.xml · derivative · entry 2 Corcoran Gavin · CIK 0001745995 · EVP of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,400 Underlying: Common Shares · 42,400 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: One-third of the common shares underlying the restricted stock unit shall vest on April 15, 2021, April 15, 2022 and April 15, 2023, subject to the Reporting Person providing continuous service to the Issuer through each such date. F3 · derivative.expiration_date: One-third of the common shares underlying the restricted stock unit shall vest on April 15, 2021, April 15, 2022 and April 15, 2023, subject to the Reporting Person providing continuous service to the Issuer through each such date. Read SEC document |
| April 15, 2020 Filed Apr 17, 2020 21:04 UTC | Sio Gene Therapies Inc. AXGT · Entity 130622 | GrantStock Option (Right to Buy) · Derivative | 63,700 | $0.00 Strike: $3.45 | $0.00 |
DisclosureSEC source: 0001209191-20-025017 · doc4.xml · derivative · entry 1 Corcoran Gavin · CIK 0001745995 · EVP of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,700 Underlying: Common Shares · 63,700 shares Expires 2030-04-14 F1 · derivative.exercise_date: The option vests over a period of four years with 25% of the common shares underlying the option vesting on April 15, 2021 and the remainder vesting in 12 equal quarterly installments thereafter, subject to Reporting Person providing continuous service to the Issuer on each such date. The option allows for early exercise, subject to the Issuer's repurchase option with respect to any unvested common shares. All common shares underlying the option will become fully vested upon a change in control, as that term is defined in the Issuer's 2015 Equity Incentive Plan Read SEC document |
| September 21, 2019 Filed Sep 24, 2019 17:15 UTC | Sio Gene Therapies Inc. AXGT · Entity 130622 | GrantRestricted Stock Units · Derivative | 32,003 | $0.00 | $0.00 |
DisclosureSEC source: 0001636050-19-000086 · wf-form4_156935971860145.xml · derivative · entry 1 Corcoran Gavin · CIK 0001745995 · EVP of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,003 Underlying: Common Shares · 32,003 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: 50% of the common shares underlying the restricted stock units vest on January 31, 2020 and the remainder vest on July 31, 2020, subject to the Reporting Person providing continuous service to the Issuer through each such date. F2 · derivative.expiration_date: 50% of the common shares underlying the restricted stock units vest on January 31, 2020 and the remainder vest on July 31, 2020, subject to the Reporting Person providing continuous service to the Issuer through each such date. Read SEC document |
| April 15, 2019 Filed Apr 17, 2019 21:17 UTC | Sio Gene Therapies Inc. AXGT · Entity 130622 | GrantStock Option ( Right to Buy) · Derivative | 200,000 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0001209191-19-025191 · doc4.xml · derivative · entry 2 Corcoran Gavin · CIK 0001745995 · EVP of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2029-04-14 F2 · derivative.exercise_date: The option allows for early exercise, subject to the Issuer's repurchase option with respect to any unvested common shares. All common shares underlying the option will become fully vested upon a change in control, as that term is defined in the Issuer's 2015 Equity Incentive Plan. F3 · derivative.exercise_date: One-third of the option will vest at such time as the Issuer's 30-day trailing volume weighted average closing stock price ("30-day VWAP") is equal to $2.12; one-third of the option will vest at such time as the Issuer's 30-day VWAP stock price is equal to $4.24; and one-third of the option will vest at such time as the Issuer's 30-day VWAP stock price is equal to $6.36, in each case subject to the Reporting Person providing continuous service to the Issuer on each such date. Read SEC document |
| April 15, 2019 Filed Apr 17, 2019 21:17 UTC | Sio Gene Therapies Inc. AXGT · Entity 130622 | GrantStock Option ( Right to Buy) · Derivative | 767,000 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0001209191-19-025191 · doc4.xml · derivative · entry 1 Corcoran Gavin · CIK 0001745995 · EVP of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 767,000 Underlying: Common Stock · 767,000 shares Expires 2029-04-14 F1 · derivative.exercise_date: The option vests over a period of four years, with one quarter of the common shares underlying the option vesting on April 15, 2020 and the remainder vesting in twelve equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer on each such date. F2 · derivative.exercise_date: The option allows for early exercise, subject to the Issuer's repurchase option with respect to any unvested common shares. All common shares underlying the option will become fully vested upon a change in control, as that term is defined in the Issuer's 2015 Equity Incentive Plan. Read SEC document |
| July 16, 2018 Filed Jul 20, 2018 18:23 UTC | Sio Gene Therapies Inc. AXON · Entity 130622 | GrantEmployee Stock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $2.46 | $0.00 |
DisclosureSEC source: 0001209191-18-043532 · doc4.xml · derivative · entry 2 Corcoran Gavin · CIK 0001745995 · EVP of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Shares · 200,000 shares Expires 2028-07-16 F2 · derivative.exercise_date: The option allows for early exercise, subject to the Issuer's repurchase option with respect to any unvested common shares. All common shares underlying the option will become fully vested upon a change in control, as that term is defined in the Issuer's 2015 Equity Incentive Plan. F3 · derivative.exercise_date: One-third of the option will vest at such time as the Issuer's stock price is equal to $7.38; one-third of the option will vest at such time as the Issuer's stock price is equal to $12.30, and one-third of the option will vest at such time as the Issuer's stock price is equal to $17.22, in each case subject to the Reporting Person providing continuous service to the Issuer on each such date. Read SEC document |
| July 16, 2018 Filed Jul 20, 2018 18:23 UTC | Sio Gene Therapies Inc. AXON · Entity 130622 | GrantEmployee Stock Option (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $2.46 | $0.00 |
DisclosureSEC source: 0001209191-18-043532 · doc4.xml · derivative · entry 1 Corcoran Gavin · CIK 0001745995 · EVP of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Shares · 250,000 shares Expires 2028-07-16 F1 · derivative.exercise_date: The option vests over a period of four years, with one quarter of the common shares underlying the option vesting on July 16, 2019 and the remainder vesting in twelve equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer on each such date. F2 · derivative.exercise_date: The option allows for early exercise, subject to the Issuer's repurchase option with respect to any unvested common shares. All common shares underlying the option will become fully vested upon a change in control, as that term is defined in the Issuer's 2015 Equity Incentive Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.